Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057 1. MORF-057 well tolerated in all dose cohorts. 2. MORF-057 achieved greater than 95% mean receptor occupancy of integrin at three highest dose levels; demonstrates ability to saturate receptor 3. Data provide early clinical proof of concept for MORF-057 as...
I am buying it at 31-32 if it finds the support within next 1-2 weeks. If not - alternatively will buy at 22-26 level. Take-profit - 44.
This might even count as a nice S/R flip. In this case see you again at ATH :D
Entry price : 32.66 Fundamentals : - Sector: Medical - Biotech - EPS % Chg (Last Qtr): 157% - EPS % Chg (Previous Qtr): -68% - 3 Year EPS Growth Rate: 0% - EPS Est % Chg (Current Yr): 0% - Sales % Chg (Last Qtr): 354% - Sales % Chg (Previous Qtr): 38% - 3-Year Sales Growth Rate: 167% - Annual Pre -Tax Margin: -249.8%
Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates MORF 16H: BUY/HOLD 40% gains(NEW) 🔸 Summary and potential trade...